Wednesday, July 8, 2026

biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactati

Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Employees
213
Programs
7
Drugs
14
Patents
72
Clinical program

MRT-6160

Phase 1 · small molecule · Healthy Volunteers

MRT-6160 for Healthy Volunteers is a Phase 1 program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).

← All Monte Rosa Therapeutics projects Phase 1 small molecule completed

Internal code MRT-6160-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Monte Rosa Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1

Clinical trials